ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Prostate Related Issues
New therapy for Enlarged Prostate
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="Vince" data-source="post: 148339" data-attributes="member: 843"><p>It is evident that the Rezum system has many strengths that endorse its use. Despite this, it is not without its disadvantages. A significant benefit of TURP is its use in incidental identification of prostate cancer, with positive detection on 4.1–16.7% of TURP specimens.<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6180381/#bibr17-1756287218793084" target="_blank">17</a> In contrast, Rezum does not collect tissue specimens; therefore, it lacks the ability to ascertain incidental cases of prostate cancer. Furthermore, the nature of the exclusion criteria limits the number of patients who qualify for the procedure. Patients with urinary retention and large prostate burdens potentially would not be eligible, excluding a significant section of patient population.</p><p>Catheterization post procedure is at the discretion of the clinician. In a pilot trial by Dixon and colleagues,<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6180381/#bibr8-1756287218793084" target="_blank">8</a> 55% of patients were catheterized prior to discharge plus an additional 17% requiring catheterization post discharge, with an average duration of catheter use of 4.1 days. Of note, many of the sites involved in this trial adopted default position of catheter placement.</p><p>There is a lack of long-term follow up; currently, there is only one RCT providing data for a period up to 36 months as part of a 5-year trial.<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6180381/#bibr10-1756287218793084" target="_blank">10</a> It can be argued that further evidence and longer-term data are required to demonstrate that the benefits provided by Rezum can be sustained. Furthermore, all evidence collected to date has been sponsored by NxThera (Maple Grove, MN, USA), which is a potential be a conflict of interest.</p><p></p><p><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6180381/" target="_blank">Rezum: a new transurethral water vapour therapy for benign prostatic hyperplasia</a></p></blockquote><p></p>
[QUOTE="Vince, post: 148339, member: 843"] It is evident that the Rezum system has many strengths that endorse its use. Despite this, it is not without its disadvantages. A significant benefit of TURP is its use in incidental identification of prostate cancer, with positive detection on 4.1–16.7% of TURP specimens.[URL='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6180381/#bibr17-1756287218793084']17[/URL] In contrast, Rezum does not collect tissue specimens; therefore, it lacks the ability to ascertain incidental cases of prostate cancer. Furthermore, the nature of the exclusion criteria limits the number of patients who qualify for the procedure. Patients with urinary retention and large prostate burdens potentially would not be eligible, excluding a significant section of patient population. Catheterization post procedure is at the discretion of the clinician. In a pilot trial by Dixon and colleagues,[URL='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6180381/#bibr8-1756287218793084']8[/URL] 55% of patients were catheterized prior to discharge plus an additional 17% requiring catheterization post discharge, with an average duration of catheter use of 4.1 days. Of note, many of the sites involved in this trial adopted default position of catheter placement. There is a lack of long-term follow up; currently, there is only one RCT providing data for a period up to 36 months as part of a 5-year trial.[URL='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6180381/#bibr10-1756287218793084']10[/URL] It can be argued that further evidence and longer-term data are required to demonstrate that the benefits provided by Rezum can be sustained. Furthermore, all evidence collected to date has been sponsored by NxThera (Maple Grove, MN, USA), which is a potential be a conflict of interest. [URL="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6180381/"]Rezum: a new transurethral water vapour therapy for benign prostatic hyperplasia[/URL] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Prostate Related Issues
New therapy for Enlarged Prostate
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top